PTC Therapeutics, Inc. (PTCT)
Market: NASD |
Currency: USD
Address: 100 Corporate Court
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Show more
📈 PTC Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$62.81
-
Upside/Downside from Analyst Target:
24.55%
-
Broker Call:
19
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
50-100%
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for PTC Therapeutics, Inc.
| Date | Reported EPS |
|---|
| 2026-05-04 (estimated upcoming) | - |
| 2026-02-25 (estimated upcoming) | - |
| 2025-11-05 (estimated upcoming) | - |
| 2025-11-04 (estimated upcoming) | - |
| 2025-08-06 (estimated upcoming) | - |
| 2025-08-05 (estimated upcoming) | - |
| 2025-05-06 | 10.04 |
| 2025-04-22 | - |
| 2025-02-27 | -2.15 |
| 2025-02-25 | - |
| 2024-11-07 | -1.39 |
| 2024-08-08 | -1.27 |
| 2024-08-07 | -1.27 |
| 2024-04-25 | -1.2 |
| 2024-04-24 | -1.2 |
| 2024-02-29 | -0.24 |
| 2024-02-28 | -0.24 |
| 2023-10-26 | -1.76 |
| 2023-10-25 | -1.76 |
| 2023-08-03 | -2.66 |
| 2023-08-02 | -2.66 |
| 2023-04-27 | -1.88 |
| 2023-04-26 | -1.88 |
| 2023-02-21 | -1.89 |
| 2023-02-20 | -1.89 |
| 2022-10-27 | -1.53 |
| 2022-10-26 | -1.53 |
| 2022-08-04 | -2.13 |
| 2022-08-03 | -2.13 |
| 2022-05-03 | -1.78 |
| 2022-05-02 | -1.78 |
| 2022-02-22 | -2.03 |
| 2022-02-21 | -2.03 |
| 2021-10-28 | -1.89 |
| 2021-10-27 | -1.89 |
| 2021-07-29 | -1.68 |
| 2021-07-28 | -1.68 |
| 2021-05-04 | -1.83 |
| 2021-05-03 | -1.83 |
| 2021-02-25 | -1.08 |
| 2021-02-24 | -1.08 |
| 2020-10-29 | -1.03 |
| 2020-10-28 | -1.03 |
| 2020-08-05 | -2.62 |
| 2020-08-04 | -2.62 |
| 2020-04-30 | -1.81 |
| 2020-04-29 | -1.81 |
| 2020-03-01 | -1.37 |
| 2019-10-28 | -1.06 |
| 2019-08-05 | -0.75 |
| 2019-05-01 | -1.29 |
| 2019-02-27 | -0.58 |
| 2018-11-04 | -1.06 |
| 2018-08-06 | -0.21 |
| 2018-05-08 | -0.46 |
| 2018-03-05 | 0.03 |
| 2017-11-01 | -0.82 |
| 2017-08-07 | -0.44 |
| 2017-05-07 | -0.85 |
| 2017-03-15 | -0.78 |
| 2016-11-01 | -1.03 |
| 2016-08-03 | -1.14 |
| 2016-05-04 | -1.22 |
| 2016-02-28 | -1.5 |
| 2015-11-08 | -1.27 |
| 2015-07-29 | -1.14 |
| 2015-05-03 | -1.15 |
| 2015-02-26 | -0.84 |
| 2014-11-05 | -0.93 |
| 2014-08-06 | -0.86 |
| 2014-05-05 | -0.58 |
| 2014-03-05 | -0.75 |
| 2013-11-13 | -0.19 |
| 2013-08-11 | -5.51 |
📰 Related News & Research
No related articles found for "ptc therapeutics".
